Skip to main content
NCBI home page
AAPS PharmSciTech logoLink to AAPS PharmSciTech
. 2007 Nov 30;8(4):156. doi: 10.1208/pt0804100

Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation

Hamdy Abdelkader 1,✉, Ossama Youssef Abdalla 2, Hesham Salem 3
PMCID: PMC2750686

Abstract

This work aims at investigating different types and levels of hydrophilic matrixing agents, including methylcellulose (MC), sodium alginate (Alg), and sodium carboxymethylcellulose (CMC), in an attempt to formulate controlled-release matrix tablets containing 25 mg baclofen. The tablets were prepared by wet granulation. Prior to compression, the prepared granules were evaluated for flow and compression characteristics. In vitro, newly formulated controlled-release tablets were compared with standard commercial tablets (Lioresal and baclofen). The excipients used in this study did not alter physicochemical properties of the drug, as tested by the thermal analysis using differential scanning calorimetry. The flow and compression characteristics of the prepared granules significantly improved by virtue of granulation process. Also, the prepared matrix tablets showed good mechanical properties (hardness and friability). MC- and Alg-based tablet formulations showed high release-retarding efficiency, and good reproducibility and stability of the drug release profiles when stored for 6 months in ambient room conditions, suggesting that MC and Alg are good candidates for preparing modified-release baclofen tablet formulations.

Keywords: Baclofen, modified release, hydrophilic matrix, drug-excipient compatibility

Full Text

The Full Text of this article is available as a PDF (332.1 KB).

Footnotes

Themed Issue: Oral Controlled Release Development and Technology

Guest Editor — Stephen A. Howard and Jian-Xin Li

References

  • 1.Theeuwes F. Oros osmotic system development. Drug Dev Ind Pharm. 1983;9:1331–1357. doi: 10.3109/03639048309046322. [DOI] [Google Scholar]
  • 2.Ahuja S. Analytical Profiles of Drug Substances and Excipients. London, UK: Academic Press; 1985. pp. 527–548. [Google Scholar]
  • 3.Merino M, Peris RJ, Torres MF, Sanchez PA, Carbonell MC, Casabo VG. Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. Biopharm Drug Dispos. 1989;10:279–297. doi: 10.1002/bdd.2510100307. [DOI] [PubMed] [Google Scholar]
  • 4.Cejudo-Ferragud E, Nácher A, Polache A, Cercós-Fortea T, Merino MC, Casabó VG. Evidence of competitive inhibition for the intestinal absorption of baclofen for phenylalanine. Int J Pharm. 1996;132:63–69. doi: 10.1016/0378-5173(95)04342-X. [DOI] [Google Scholar]
  • 5.Hugenholtz H, Nelson RF, Dehoux E. Intrathecal baclofen: the importance of catheter position. Can J Neurol Sci. 1993;20:165–170. doi: 10.1017/s0317167100047776. [DOI] [PubMed] [Google Scholar]
  • 6.Martindale . Martindale: The Complete Drug Reference. Chicago, IL: Pharmaceutical Press; 2005. pp. 1758–1759. [Google Scholar]
  • 7.Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimization in the treatment of Parkinson’s disease. Clin Pharmacokinet. 1996;30:463–481. doi: 10.2165/00003088-199630060-00004. [DOI] [PubMed] [Google Scholar]
  • 8.Erni W, Held K. The hydrodynamically balanced system: a novel principle of controlled drug release. Eur Neurol. 1987;27:21–27. doi: 10.1159/000116171. [DOI] [PubMed] [Google Scholar]
  • 9.Dempski RE, Scholtz EC, Oberholtzer ER, Yeh KC. Pharmaceutical design and development of a Sinemit controlled release formulation. Neurology. 1989;39:20–24. doi: 10.1159/000153826. [DOI] [PubMed] [Google Scholar]
  • 10.Yeh KC, August TF, Bush DF. Pharmacokinetics and bioavailability of Sinemit CR: a summary of human studies. Neurology. 1989;39:25–38. [PubMed] [Google Scholar]
  • 11.LeWitt PA, Nelson MV, Berchou RC. Controlled-release carbidopa/levodopa (Sinemit 50/200 CR4): clinical and pharmacokinetic studies. Neurology. 1989;39:45–53. [PubMed] [Google Scholar]
  • 12.Crevoisier C, Hoevels B, Zürcher G, Da Prada M. Bioavailability of 1-dopa after Madopar HBS administration in healthy volunteers. Eur Neurol. 1987;27:36–46. doi: 10.1159/000116173. [DOI] [PubMed] [Google Scholar]
  • 13.Marion MH, Stocchi F, Malcolm SL, Quinn NP, Jenner P, Marsden CD. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson’s disease. Eur Neurol. 1987;27:54–58. doi: 10.1159/000116193. [DOI] [PubMed] [Google Scholar]
  • 14.Cruaud O, Benita S, Benoit JP. The characterization and release kinetics evaluation of baclofen microspheres designed for intrathecal injection. Int J Pharm. 1999;177:247–257. doi: 10.1016/S0378-5173(98)00350-0. [DOI] [PubMed] [Google Scholar]
  • 15.Lagarce F, Renaud P, Faisnat N, et al. Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model. Eur J Pharm Biopharm. 2005;59:449–459. doi: 10.1016/j.ejpb.2004.08.013. [DOI] [PubMed] [Google Scholar]
  • 16.Zierski J, Muller H, Dralle D, Wurdinger T. Implanted pump systems for treatment of spasticity. Acta Neurochir Suppl (Wien) 1988;43:94–99. doi: 10.1007/978-3-7091-8978-8_21. [DOI] [PubMed] [Google Scholar]
  • 17.Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia. 1991;29:48–64. doi: 10.1038/sc.1991.7. [DOI] [PubMed] [Google Scholar]
  • 18.Hugenholtz H, Nelson RF, Dehoux E, Birkerton R. Intrathecal baclofen for intractable spinal spasticity—a double-blind cross-over comparison of 6 patients. Can J Neurol Sci. 1992;19:188–195. [PubMed] [Google Scholar]
  • 19.Hugenholtz H, Nelson RF, Dehoux E. Intrathecal baclofen: the importance of catheter position. Can J Neurol Sci. 1993;20:165–167. doi: 10.1017/s0317167100047776. [DOI] [PubMed] [Google Scholar]
  • 20.Ritger PL, Peppas NA. A simple equation for description of solute release, II: Fickian and anomalous release from swellable devices. J Control Release. 1987;5:37–42. doi: 10.1016/0168-3659(87)90035-6. [DOI] [PubMed] [Google Scholar]
  • 21.Sato H, Miyagawa Y, Okabe T, Miyajima M, Sunada H. Dissolution mechanism of diclofenac sodium from wax matrix granules. J Pharm Sci. 1997;86:929–934. doi: 10.1021/js960221w. [DOI] [PubMed] [Google Scholar]
  • 22.Raghuram RK, Srinivas M, Srinivas R. Once-daily sustained-release matrix tablets of nicorandil: formulation and in vitro evaluation.AAPS PharmSciTech [serial online]. 2003;4:E61. [DOI] [PMC free article] [PubMed]
  • 23.Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. Philadelphia, PA: Lea and Febiger; 1987. pp. 317–318. [Google Scholar]
  • 24.Korsmeyer RW, Gumy R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35. doi: 10.1016/0378-5173(83)90064-9. [DOI] [Google Scholar]
  • 25.Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60:110–112. [PubMed] [Google Scholar]
  • 26.Peppas NA, Sahlin JJ. A simple equation for the description of solute release, III: coupling of diffusion and relaxation. Int J Pharm. 1989;57:169–175. doi: 10.1016/0378-5173(89)90306-2. [DOI] [Google Scholar]
  • 27.Ritger PL, Peppas NA. A simple equation for description of solute release, I: Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release. 1987;5:23–35. doi: 10.1016/0168-3659(87)90034-4. [DOI] [PubMed] [Google Scholar]
  • 28.Talukdar MM, Rommbaut P, Kinget R. Comparative study on xanthan gum and hydroxypropyl methylcellulose as matrices for controlled-release drug delivery. Int J Pharm. 1996;129:233–241. doi: 10.1016/0378-5173(95)04355-1. [DOI] [Google Scholar]
  • 29.Reza MS, Abdul Quadir M, Haider SS. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. J Pharm Pharm Sci. 2003;6:282–291. [PubMed] [Google Scholar]
  • 30.Mockel JE, Lippold BC. Zero-order release from hydrocolloid Matrices. Pharm Res. 1993;10:1066–1070. doi: 10.1023/A:1018931210396. [DOI] [PubMed] [Google Scholar]
  • 31.Pharmaceutical Codex. Principles and Practice of Pharmaceutics. London, UK: Pharmaceutical Press; 1994. pp. 178–186. [Google Scholar]
  • 32.O’Neil MJ, editor. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th ed. Whitehouse Station, NJ: Merck & Co; 2001. pp. 164–165. [Google Scholar]
  • 33.Martin A, editor. Micromeritics. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. pp. 423–454. [Google Scholar]
  • 34.Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled release dosage forms. Int J Pharm Technol Prod Manuf. 1984;5:1–9. [Google Scholar]
  • 35.Khan KA, Rhodes CT. Evaluation of different viscosity grades of sodium carboxy methylcellulose as tablet disintegrants. Pharm Acta Helv. 1975;50:99–102. [PubMed] [Google Scholar]
  • 36.Shah NH, Lazarus JH, Jarwoski CL. Carboxy methylcellulose: effect of degree of polymerization and substitution on tablet disintegration and dissolution. J Pharm Sci. 1981;70:611–613. doi: 10.1002/jps.2600700609. [DOI] [PubMed] [Google Scholar]
  • 37.Al-Hmoud H, Efentakis M, Choulis NH. A controlled release matrix using a mixture of hydrophilic and hydrophobic polymers. Int J Pharm. 1991;68:R1–R3. doi: 10.1016/0378-5173(91)90155-H. [DOI] [Google Scholar]
  • 38.Esmail MN, Yousry ME, Sayed HK. Effect of accelerated storage conditions on the dissolution and bioavailability of amitriptyline from sustained-release capsules. SPJ. 1996;4:92–98. [Google Scholar]
  • 39.Braco SA, Lamas MC, Salamon CJ. In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices. J Pharm Pharm Sci. 2002;5:213–219. [PubMed] [Google Scholar]
  • 40.Goetz CG, Tanner CM, Carrol VS. Controlled-release Sinemet. Neurology. 1987;37:1567–1575. doi: 10.1212/wnl.37.9.1567. [DOI] [PubMed] [Google Scholar]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES